Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- City of Hope
- Harvard University
- National University of Singapore
- Indiana University
- University of Maryland, Baltimore
- Nanyang Technological University
- University of British Columbia
- University of Michigan
- University of Colorado
- Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S)
- Center for Biologics Evaluation and Research (CBER)
- Cold Spring Harbor Laboratory
- Tokyo University of Science
- UNIVERSITY OF MELBOURNE
- University of Cincinnati
- University of Kansas Medical Center
- Vanderbilt University
- Yale University
- BU Pulmonary
- Cellular and Molecular Therapeutics Branch, NHLBI, NIH
- Dana-Farber Cancer Institute (DFCI)
- Francis Crick Institute
- H. Lee Moffitt Cancer Center & Research Institute
- Microbiomes Institute — University of South Florida
- Monash University
- The Jiang Lab, The Icahn School of Medicine at Mount Sinai
- The University of Queensland
- The University of Texas MD Anderson Cancer Center
- The University of Texas Southwestern Medical Center (UT Southwestern Medical Center)
- University of Basel
- University of Birmingham
- University of Maryland School of Medicine, Baltimore
- University of Michigan (U-M)
- University of North Carolina
- University of Nottingham
- University of Nottingham;
- University of Oslo
- University of Otago
- University of Texas Rio Grande Valley
- University of Texas at Austin
- Université de Caen Normandie
- Université de Strasbourg
- Weill Cornell Medicine - Chandwani Laboratory
- Zintellect
- 34 more »
- « less
-
Field
-
Microbiomes Institute — University of South Florida | Tampa, Florida | United States | about 17 hours ago
Institute for Translational Virology & Innovation. Our interdisciplinary approach combines microbiology, immunology, immunometabolism, multi-omics, mouse models, and organoids, with access to patient-derived
-
driving disease initiation and progression, using a combination of mouse models, patient-derived samples, and high-throughput technologies, including next-generation sequencing, flow cytometry, and
-
pharmacology, preclinical oncology, and mouse therapeutic efficacy studies to contribute to a federally funded translational research program focused on the preclinical development of novel small-molecule
-
of the disorder and the resulting splicing dysfunction, and to establish appropriate mouse models, with the ultimate goal of developing an RNA-targeted therapy. This position offers the opportunity to work at the
-
of the postdoctoral contract. Practical experience with in vivo mouse experimentation is required. Experience with PDX models is strongly desirable. Experience with patient-derived tumor organoids is considered
-
these processes influence susceptibility to infectious and inflammatory diseases. We integrate state-of-the-art mouse models, high-dimensional immune profiling, single-cell genomics, and functional immunology
-
needed to improve outcome. They must be willing: to work with mouse models of cancer to work flexibly and out-of-hours, when necessary, to fulfil the needs of the research project (and able) to keep up
-
mouse models to investigate the role of protein arginine methylation in the regulation of chromatin biology, RNA splicing, and RNA modification in mammalian cells. Your qualifications should include: A
-
WNT/PCP genetic models with diet-induced maternal obesity to quantify embryonic cardiac defects and define the signaling endpoints where genetic and environmental insults converge, using mouse
-
. The lab employs a combination of cellular and molecular techniques, mouse models and patient samples to assess these areas. For more information on Dr. Vasavada’s research please visit here .